The MUSCA Trial

DREAM
Phase II/III dose ranging efficacy and safety study

MENSA
Phase III exacerbation study

SIRIUS
Phase III oral corticosteroid sparing study

COSMOS
Phase III long-term efficacy and safety study

Severe asthma: a form of the disease in which people with asthma struggle to control their symptoms and may continue to have asthma attacks even when they take high doses of medicine.

Eosinophilic phenotype: Eosinophils are a type of white blood cell that in some severe asthma patients contribute to inflammation in the lungs, making breathing difficult and increasing the risk of an asthma attack. It is estimated that 2% to 5% of patients with asthma have an eosinophilic phenotype.

The Nucala® (mepolizumab) MUSCA Trial
(Mepolizumab adjUnctive therapy in subjects with Severe eosinophilic Asthma)
Phase III study

References

